Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children that shares many features of developing skeletal muscle. TBX2, a T-box family member, is highly upregulated in tumor cells of both major RMS subtypes where it functions as an oncogene. TBX2 is a repressor that is often overexpressed in cancer cells and functions in bypassing cell growth control, including the repression of the cell cycle regulators p14 and p21. We have found that TBX2 directly represses the tumor-suppressor phosphatase and tensin homolog (PTEN) in both RMS and normal muscle. Exogenous expression of TBX2 in normal muscle cells downregulates PTEN, and depletion or interference with TBX2 in RMS cells upregulates PTEN. Human RMS tumors show high levels of TBX2 and correspondingly low levels of PTEN. The expression of PTEN in clinical RMS samples is relatively uncharacterized, and we establish that suppression of PTEN is a frequent event in both subtypes of RMS. TBX2 represses PTEN by directly binding to the promoter and recruiting the histone deacetylase, HDAC1. RMS cells have high levels of activated AKT owing to the deregulation of phosphoinositide-3 kinase (PI3K) signaling, and depletion or interference with TBX2, which upregulates PTEN, results in a reduction of phospho-AKT. We have also found that the highly related T-box family member TBX3 does not repress PTEN in the muscle lineage. This work suggests that TBX2 is a central component of the PTEN/PI3K/AKT signaling pathway deregulation in RMS cells and that targeting TBX2 in RMS tumors may offer a novel therapeutic approach for RMS.
INTRODUCTION
Phosphatase and tensin homolog (PTEN) is a well-known tumor suppressor and loss or inactivation of PTEN has been implicated in many types of cancer. 1 PTEN has an essential role in normal development, physiology and tumor suppression. Homozygous deletion of Pten causes embryonic lethality, suggesting that PTEN is essential for embryonic development. 2 Heterozygous deletion of Pten promotes tumorigenesis of several cancers, including medulloblastoma, 3 intestinal tumors 4 and prostate cancer. 5 In medulloblastoma, patients whose tumor express a low-to-absent level of PTEN show a worse survival ratio, 3 and in prostate cancer, PTEN level inversely correlates with occurrence of invasive prostate cancer. 5 Germline mutation of PTEN causes multiple disease syndromes, including Cowden disease, Bannayan-RileyRuvalcaba syndrome and Lhermitte-Duclos syndrome. 1 PTEN is known to function at the cytoplasmic membrane to antagonize the phosphoinositide-3 kinase (PI3K) signaling pathway by dephosphorylating phosphatidylinositol-3,4,5-triphosphate (PIP3), the important secondary-messenger molecule of PI3K pathways. 6 Inactivation of PTEN results in activation of the PI3K/AKT pathway and subsequent increase in cell cycle progression, migration and survival. 7, 8 PTEN also functions in the nucleus where PTEN is indicated to have multiple roles, including cell cycle control 9, 10 and stabilizing chromosomes.
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In the cytoplasm, PTEN prefers PIP3 as the major biological phosphoprotein substrate for dephosphorylation and converts PIP3 to PIP2. 12 PIP3 is absent or very low in quiescent cells but is rapidly upregulated by PI3K in response to growth factors or extracellular signaling. PIP3 is the major activator of AKT. AKT is recruited via PIP3 to the plasma membrane, where AKT can then be fully activated by phosphorylation.
In the muscle, activation of PI3K/AKT pathway induced by serum starvation is crucial for myoblast differentiation in vitro. Loss of PTEN significantly promotes AKT phosphorylation and enhances myoblast differentiation. 13 Surprisingly, a musclespecific depletion of Pten driven by muscle creatine kinase promoter was found to protect mice from insulin resistance and did not grossly affect muscle histology or induce tumor development. 14 In the nucleus, PTEN regulates cell cycle progression by downregulating transcriptional expression and protein stability of cyclin D1, as well as by inhibiting its nuclear localization.
established that mutation of PTEN is not a frequent event in RMS cells, but the expression of PTEN in clinical RMS samples has not been characterized. In RMS cells, the fusion protein PAX3-FOXO1 has been shown to contribute to repression of PTEN. 20 Depletion of PAX3-FOXO1 in RMS cells upregulated PTEN and exogenous expression of PAX3 in C2C12 cells downregulated PTEN. 20 In both C2C12 normal myoblasts and RMS cells, the level of PTEN has been shown to be inversely correlated with AKT serine 473 phosphorylation, 21 which is mediated by the rapamycininsensitive mammalian target of rapamycin (mTOR) complex (mTORC2) 22 and required for full activation of AKT. 23 It has also been shown that microRNA miR-183 functions as an oncogene in RMS cells by targeting the transcription factor early growth response protein 1 (EGR1), which is an activator of PTEN. 24 Here we show that TBX2 directly represses PTEN in RMS cells. The repression is mediated at least in part through recruitment of the histone deacetylase HDAC1 to the PTEN promoter. TBX2 expression and PTEN expression are inversely correlated in both RMS cell lines and human RMS tumor samples representing both embryonal RMS (ERMS) and alveolar RMS (ARMS) cells. We show that PTEN expression is suppressed in a majority of clinical RMS samples representing both subtypes, suggesting that the repression of PTEN is a frequent event in RMS. Depletion or interference with TBX2 in RMS cells upregulates PTEN and reduces phospho-AKT. A highly related factor, TBX3, which has been shown to repress PTEN in other cell types, does not repress PTEN in the muscle lineage. These data suggest that TBX2 represents an important new target for inhibiting the PI3K pathway implicated in RMS proliferation and progression.
RESULTS

PTEN is induced upon muscle cell differentiation
To understand the expression pattern of PTEN during normal skeletal muscle cell differentiation, we first assayed for the expression of PTEN in proliferating and differentiated C2C12 cells, a murine cell line commonly used as a model of myogenesis. We found that PTEN was upregulated at the RNA level during differentiation (Figure 1a ). To confirm this result, the experiment was repeated in primary murine myoblasts, and we found that PTEN was strongly upregulated upon differentiation in these cells as well (Figure 1b) . The upregulation of PTEN was also observed at the protein level in both differentiated primary myoblasts and C2C12 cells (Figure 1c) . PTEN activity is also regulated by phosphorylation of the C-terminus, which inactivates the protein. 25 Using an antibody specific to the phosphorylation of Ser380/Thr392/383 on PTEN, we found that p-PTEN could be detected in differentiated C2C12 cells, indicating that both the expression and phosphorylation of PTEN is regulated in normal muscle (Figure 1c) . Immunocytochemistry with specific antibodies against PTEN displayed a robust increase of PTEN protein upon C2C12 differentiation in both the cytoplasm and nucleus (Figure 1d ). These data demonstrate that PTEN is upregulated upon differentiation and regulated by phosphorylation in normal skeletal muscle cells. specimens. These cases were previously diagnosed as ARMS (n = 72), ERMS (n = 123), pleomorphic RMS (n = 18) and undifferentiated RMS (n = 9) subtypes. Representative sections were immunostained for PTEN and the signal graded as intact or lost ( Figure 2a ). We found that PTEN expression was lost in the majority of both ERMS and ARMS cases (Figure 2b ). In all, 87.8% of ERMS tumors and 80.6% of ARMS tumors did not express PTEN (Figure 2b) . A similar trend was noted in undifferentiated RMS, with PTEN loss detected at 88.9% (Figure 2b ). PTEN expression was more retained in pleomorphic RMS, with the loss of PTEN detected in only 66.7% of cases (Figure 2b ). One limitation of the study is the lack of molecular genetic data for FOXO1 in early archival cases for ARMS, thus the status of the PAX-FOXO1 fusion protein, which has been shown to repress PTEN, 20 is not known in these samples. The data show that the absence of PTEN is a highly frequent event in human RMS tumors, including ERMS, which do not contain the PAX-FOXO1 fusion protein.
PTEN expression is decreased in RMS cells
Next we sought to validate our finding in representative RMS cell lines to provide appropriate cell models for functional studies defining the mechanism of repression of PTEN. The expression of PTEN was assayed in both RMS cell lines and primary tumor cells. We found that the PTEN transcript was reduced when compared with proliferating C2C12 cells in RH30, RD, RD2 and RH28 cell lines as well as in primary cells derived from mouse tumor models of RMS that represent both major tumor subtypes (Figure 2c ). The protein expression of PTEN was detected with antibodies against PTEN that recognize both murine and human proteins. We found that PTEN protein expression was reduced in all the tested RMS cells when compared with proliferating C2C12 cells (Figure 2d ). We also examined p-PTEN, but, corresponding to the low expression of PTEN, p-TEN levels were not detectable in RMS cells (Figure 2e ) Immunostaining for PTEN confirmed the low level of PTEN expression in RMS cell lines (Figure 2f ). To correlate the expression of PTEN with TBX2 expression in these cell lines, we also performed immunocytochemistry for TBX2 (Figure 2g ). Consistent with our previously published western blotting analysis, 26 we found that TBX2 was robustly upregulated in RMS cells and correlated inversely with PTEN expression. PTEN expression is inversely correlated with TBX2 expression in human tumors To determine whether TBX2 was also inversely correlated with PTEN in human RMS tumors, we performed immunohistochemistry for TBX2 and PTEN in human clinical RMS tumor samples, which included both ERMS and ARMS tumor samples (Figure 3a) . We found that TBX2 was highly expressed in human tumor samples of both ERMS and ARMS subtypes when compared with normal human tissue. We then performed immunohistochemistry for PTEN in the same human clinical RMS tumor samples and found that RMS tumors displayed low levels of PTEN protein when compared with normal muscle tissue (Figure 3b) . The result agrees with our previous results in RMS cell lines and primary tumor cells from engineered RMS mice. The inverse expression pattern of PTEN and TBX2 suggests that PTEN is a potential downstream target gene of TBX2 in RMS.
PTEN expression is repressed by TBX2
To determine whether PTEN expression is repressed by TBX2, 10T1/2 cells, a fibroblast cell line which can be induced to express muscle-specific genes upon transfection with muscle regulatory factors, 27 were transfected with an expression construct for TBX2 in combination with expression constructs for myogenin or MyoD and gene expression changes were determined for PTEN. When 10T1/2 cells were transfected with myogenin or MyoD to induce skeletal muscle differentiation, PTEN expression was upregulated, but co-transfection with TBX2 significantly inhibited PTEN expression, suggesting that TBX2 does repress PTEN (Figure 4a ). To confirm this result, a stable C2C12 cell line overexpressing TBX2 was assayed for PTEN expression. We found that ectopically expressed TBX2 markedly reduced PTEN at both the RNA ( Figure 4e). We also used a dominant-negative construct of TBX2 (dnTBX2), which lacks the C-terminal domain of TBX2 necessary for transcriptional repression and interaction with HDAC1 but retains amino acids 1-301 of the T-box DNA-binding activity of TBX2, thus blocking the function of endogenous TBX2. 28 The expression of dnTBX2 was confirmed by western blotting analysis ( Figure 4f ). We found that stable expression of dnTBX2 in RH30 cells also led to an upregulation of PTEN expression (Figure 4g ). The upregulation of PTEN by either depletion of TBX2 or expression of dnTBX2 was confirmed by western blotting analysis ( Figure 4h ). Western blotting was also probed for p-PTEN, but p-PTEN was not detected in the presence of shTBX2 or dnTBX2 (data not shown). Taken together, these results suggest that TBX2 represses PTEN expression in both normal muscle cells and RMS cells.
TBX2 inhibits PTEN by recruiting HDAC1 to the promoter We used PTEN promoter-specific luciferase constructs to determine promoter elements of PTEN that were required for TBX2-dependent repression. The promoter proximal elements of the PTEN promoter are diagrammed in Figure 5a To investigate the molecular mechanism of TBX2 repression on the PTEN promoter, we performed chromatin immunoprecipitation (ChIP) assays for TBX2 and the class I histone deacetylase, HDAC1, on the PTEN promoter as TBX2 has been shown to recruit HDAC1 to target gene promoters. 29 ChIP assays were also used to assay for the acetylation status of histones by examining the acetylation of lysine 9 and 18 on histone H3 (H3K9,18 ac ). We found that, in C2C12 cells expressing exogenous TBX2, TBX2 (Figure 5c ) and HDAC1 ( Figure 5d ) were bound to the PTEN promoter. In C2C12 cells expressing vector, this binding was not observed (Figures 5c and d) . The binding of TBX2 and HDAC1 was concomitant with a reduction in histone H3K9,18 ac at the PTEN promoter (Figure 5e ).
To determine whether TBX2 and HDAC1 bound to the PTEN promoter in RMS cells, ChIP assays for TBX2 and HDAC1 were repeated in RD and RH30 cells, which express high amounts of endogenous TBX2. We found that both TBX2 and HDAC1 bound to the PTEN promoter in both RH30 (Figure 5f ) and RD (Figure 5g ) cells. To determine whether the binding of HDAC1 was dependent on TBX2, TBX2 was depleted with shRNA construct in RH30 cells, and we found that the occupancy of both TBX2 and HDAC1 was reduced in TBX2-depleted RH30 cells (Figure 5f ). To determine whether HDACs were required for the repression mediated by TBX2, C2C12 cells expressing TBX2 or a vector control were treated with the class I and class II HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) while differentiating. We found that the addition of SAHA blocked the repression of PTEN by TBX2 (Figure 5h ).
Low level of PTEN is related with high activity of AKT PTEN acts as a negative regulator of the PI3K/AKT signaling pathway. To correlate AKT activity with PTEN expression in normal myoblasts and RMS cells, we assayed for activated AKT by western blotting assays with antibodies against both phosphorylated (pAKT) and total AKT. The phosphorylation status of Ser473 on AKT, the target of mTOR2, was used to detect activated AKT. We found that while the total amount of AKT protein was very similar in RMS cells (RH30 and RD) compared with C2C12 cells, the RMS cell lines contained remarkably elevated pAKT (Figure 6a) . It has been shown that transfection of wild-type PTEN into RMS and C2C12 cells results in reduced AKT phosphorylation. 21 As we show here that TBX2 represses PTEN, we asked whether depletion or interference with TBX2 would result in reduced phosphorylation of AKT. RH30 and RD cells were transfected with shTBX2 or dnTBX2 and assayed for the phosphorylation of Ser473. We found that either depletion or interference with TBX2 results in reduced pAKT (Figure 6b ). These results suggest that the high activity of PI3K/ AKT signaling is modulated by decreased PTEN expression in RMS mediated by TBX2.
TBX3 does not repress PTEN in skeletal muscle cells TBX2 and TBX3 are highly related members of the T-box family that both function as repressors. In several cancer types, TBX2 and TBX3 function together to regulate cancer proliferation, metastasis and invasion. 30, 31 TBX3 has previously been shown to be both a repressor of myogenesis in C2C12 cells 32 and a direct repressor of PTEN in head and neck squamous cell carcinoma. 33 Thus we sought to determine whether TBX3 had a similar role to TBX2 in skeletal muscle cells and RMS. We have shown that TBX2 is sharply downregulated upon C2C12 differentiation, 26 so we assayed for the expression of TBX3 during C2C12 differentiation. We found that TBX3 was robustly expressed in C2C12 cells and that the expression did not decrease upon differentiation (Figure 7a ). We next assayed RMS cells for TBX3 and found that TBX3 was reduced in expression relative to the level seen in C2C12 cells (Figure 7b ). Although reduced in expression, TBX3 was detectable in the RH28 and RD2 cell lines but was not detectable in RH30 or RD cell lines. We also assayed for the expression of TBX3 in human RMS tumor samples by immunostaining for TBX3 and found that TBX3 was expressed in normal tissue as well as in RMS tumor tissue (Figure 7c ). TBX3 did not appear to be upregulated or downregulated with respect to normal tissue. Taken together, these data show that TBX3 expression patterns are entirely different from that of TBX2 in both normal skeletal muscle and RMS cells, thus suggesting that TBX3 has an independent function in the muscle lineage.
To determine whether TBX3 represses PTEN in the muscle, an expression construct for TBX3 was stably expressed in C2C12 cells. The exogenous expression of TBX3 was confirmed by RNA ( Figure 8a ) and protein analysis (Figure 8b ). We next assayed for PTEN expression and found that no repression of PTEN was observed at the RNA (Figure 8c *** *** *** *** *** lineage, including RMS cells. To determine whether TBX3 repressed myogenesis as we have shown for TBX2, we also assayed for muscle-specific gene expression in the TBX3-expressing cell line described above. C2C12 cells expressing exogenous TBX3 or vector control were differentiated for 2 days and examined for gene expression of genes normally induced upon differentiation, including actin (Acta1), leiomodin2 (Lmod2), troponin 1, type 2 (Tnni2) and p21 (Cdkn1a). We have previously shown that exogenous expression of TBX2 represses each of these genes. 26 We found that TBX3 expression had no effect on the expression of any of these genes (Figure 8e ). To confirm our results, expression constructs for both TBX2 and TBX3 were transiently transfected into C2C12 cells, and cells were assayed for gene expression after 1 day of differentiation. We found that TBX2 robustly repressed the expression of Acta1, Tnni2, Lmod2 and Cdkn1a while TBX3 had no significant effect on the expression of these genes (Figure 8f ). The expression of PTEN was also assayed and we found that TBX2, but not TBX3, repressed PTEN (Figure 8g ).
DISCUSSION
The role of altered PI3K signaling in RMS origin and progression is well known. We show here that the tumor-suppressor PTEN, which is a negative regulator of the PI3K pathway, is downregulated in a majority of RMS tumors and that TBX2, a novel oncogene in RMS, is a direct regulator of PTEN. Thus TBX2 represents an important new target for targeting aberrant PI3K activity in RMS cells. It has been shown that both the PI3K/AKT/mTOR pathway and the RAS/RAF/MEK (mitogen-activated extracellular signal-regulated kinase)/ERK (extracellular signal-regulated kinase) pathway are active in RMS cells, leading to resistance in treating either pathway alone. However, co-inhibition of both pathways has reduced tumor growth in xenograft models. 34 As p21 can be induced by MEK/ERK pathway inhibition in RMS cells, 35 and as we have previously shown that TBX2 regulates p21 and p14, 26 this suggests that targeting TBX2 might block downstream targets of both the PI3K/AKT/mTOR pathway and the RAS/RAF/MEK/ERK pathway.
It was surprising that the highly related T-box family member TBX3 did not regulate PTEN in our experiments. TBX3 is a known regulator of PTEN in head and neck carcinoma and was shown to repress PTEN in both HeLa and HEK293 cells. 33 However, the distinct roles of TBX2 and TBX3 in the muscle lineage are not entirely surprising. TBX2 and TBX3 have been shown to be overexpressed in a number of cancers, including breast, pancreatic, ovarian, liver, cervical and melanoma. [36] [37] [38] [39] However, TBX2 and TBX3 have also been shown to exhibit mutually exclusive expression in melanoma cell lines 40 and the homologs have distinct functions in embryonic development and cancer. 29, 30, 36, 39, [41] [42] [43] [44] [45] TBX2 and TBX3 have distinct roles in cancer progression, with TBX2 functioning as a pro-proliferation factor and TBX3 promoting migration and invasion. 46, 47 Recent work has shown that the antiproliferative function of transforming growth factor-β1 is mediated through repression of TBX2 by TBX3. 28 We do not currently understand the function of TBX3 in the skeletal muscle, but it is expressed throughout differentiation, suggesting that it does have a role in myogenesis. However, overexpression of TBX3, unlike TBX2, is not sufficient to alter myogenesis.
PAX3 and the PAX3/FOXO1 fusion found in ARMS tumors have also been shown to repress PTEN. 20 Depletion of PAX3/FOXO1 in ARMS cells lines or exogenous expression of PAX3 in C2C12 cells repressed PTEN. 20 PAX3 was shown to bind to the PTEN promoter, but the repression mechanism is unclear as PAX3 and PAX3/FOXO1 are known transcriptional activators. 48 PAX3 does interact with negative modulators such as DAXX, but the PAX3-FOXO1 fusion protein is unresponsive to DAXX. 49 PAX3 has also been shown to activate TBX2 in melanoma cells, 50 suggesting that PAX3 might regulate TBX2 in RMS cells as well. Thus the negative regulation of PTEN by PAX3 may be mediated through TBX2.
PTEN is also known to be regulated in several cell types by the transcription factor EGR1. 51, 52 EGR1 binds to the PTEN promoter and activates expression. 52 Intriguingly, TBX2 has been shown to repress the tumor-suppressor NDRG1 through an interaction with EGR1. 47 TBX2 requires EGR1 to target the promoter and repress NDRG1. 47 These results suggest that TBX2 may repress the EGR1-dependent gene program, including PTEN. EGR1 also regulates a number of other key tumor-suppressor genes, thus the repression of the EGR1 program by TBX2 has important implications for growth control and oncogenesis. Understanding whether this mechanism is active in RMS cells will be an important future direction for our studies.
The regulation of several key signaling pathway components and cell cycle regulators by TBX2 strongly suggests that TBX2 is an important target for therapeutic development. We have shown the depletion or interference with TBX2 in the ARMS cell line RH30 completely blocks tumor formation in vivo. 26 Targeting TBX2 in RMS tumors may offer a novel therapeutic approach for controlling the proliferation and progression of this disease. In addition, TBX2 has been shown to be an oncogene in several cancers, suggesting that therapies designed to target TBX2 may be useful in the treatment of many cancers. 33 Plasmid EMSV-myogenin was a gift of Dr D Edmondson, UT Medical School at Houston, TX, USA and the MyoD expression construct of pEMCIIs was provided by Dr Andrew Lassar, Harvard Medical School, Boston, MA, USA. The expression construct for TBX2 (pEF TBX2) was described previously. 26 Luciferase activity was determined using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). 10T1/2 cells were seeded at a density of 5 × 10 3 cell per well in 96-well plates and transfected with 0.3 μg of DNA. Transfections were normalized to Renilla luciferase. Transfections were performed in triplicate, and all data sets were repeated three times.
MATERIALS AND METHODS
Quantitative real-time PCR RNA was isolated from cells by Trizol extractions (Invitrogen). Following treatment with DNase (Promega), 2 μg of total RNA was reversed transcribed with MultiScribe MuLV reverse transcriptase (Applied Biosystems, Grand Island, NY, USA). cDNA equivalent to 40 ng was used for quantitative PCR amplification (Applied Biosystems) with SYBR green PCR master mix (Applied Biosystems). Samples in which no reverse transcriptase was added were included for each RNA sample. The relative levels of expression of genes were normalized according to those of HPRT1. Quantitative PCR data were calculated using the comparative Ct method (Applied Biosystems). S.ds. from the mean of the [Δ] Ct values were calculated from three independent RNA samples. PTEN and TBX3 were amplified using primers pTEN m/h F 5′-GCTATGGGATTTCCTGCAG-3′, R 5′-CTAGCTGTGGTGGGTTATGG-3′ and TBX3 m/h F 5′-TGATGGACATT ATAGCTGCTGA-3′, R 5′-AGTGACGACTTTGGACATCC-3′. Primers against LMOD2, TNNI2, ACTA1 and HPRT were previously described, 54 as were primers against CDKN1A. 26 Where possible, intron spanning primers were used. All quantitative PCR was performed in triplicate, and three independent RNA samples were assayed for each time point. For measurements of relative gene expression (fold stimulation), a fold change was calculated for each sample pair and then normalized to the fold change observed at HPRT. 
Western blotting analysis
Chromatin immunoprecipitation assays
ChIP assays were performed and quantified as described previously 55 with the following modifications: 1 × 10 7 cells were used for each immunoprecipitation and protein A agarose beads (Invitrogen) were used to immunoprecipitate the antibody:antigen complexes. The following antibodies were used: anti-TBX2 (C-17, Santa Cruz Biotechnology), anti-HDAC1 (10E2, Cell Signaling) and anti-H3K9,18 ac (gift of Dr S Dent, UT MD Anderson Cancer Center). Rabbit IgG (Santa Cruz Biotechnology) was used as a non-specific control. Primers against the PTEN promoters were PTEN E2 F 5′-GGAATTTGGAAAGTTCCCC-3′ and R 5′-GTACGGAACGGTAGGAAGCT-3′. Primers against a gene desert region of Chr. 19 were previously described. 26 The 
Immunocytochemistry
Cells were grown on cover slips, fixed with paraformaldehyde, incubated with goat serum and 1.0% NP-40 for 1 h and washed with PBS. Primary antibodies anti-PTEN (559600, BD Pharmingen) and anti-TBX2 (gift of C Goding, University of Oxford) were incubated overnight at 4°C, washed with PBS and detected by Alexa Fluor-488 goat anti-mouse antibody (1:500, Invitrogen). Cell nuclei were then stained by incubating with DAPI (4,6-diamidino-2-phenylindole; 1 μM, Invitrogen) for 5 min. At least three biological replicates were performed for each experiment.
Primary human RMS tumor samples on slides and accompanying pathology reports with no patient information except age and sex were obtained from the Nationwide Children's Hospital Biopathology Center, Colombus, OH, USA. Samples were fixed by 3% H 2 O 2 in methanol for 20 min at room temperature, washed in PBS and blocked by 0.1% Triton X-100 TBS solution supplemented with 1.5% Normal Goat Serum (1.5% Normal Donkey Serum for TBX3 primary antibodies) overnight at 4°C. Primary antibodies included anti-PTEN (559600, BD Pharmingen), anti-TBX2 (gift of C Goding, University of Oxford) and anti-TBX3 (A-20, Santa Cruz Biotechnology). Primary antibodies were incubated for 2 h at room temperature and then washed with 0.1% Triton X-100 TBS before adding the corresponding secondary antibodies Alexa Fluor-488 goat anti-mouse or Alexa Fluor-488 donkey anti-goat antibody (1:500, Invitrogen) for incubation for 1 h at room temperature. Mounting medium, including DAPI, was used for cell nuclei staining. Ten patient samples, with at least two slides per patient, were used for each antibody. Representative slides are shown.
The 222 archival samples derived from RMS specimens were submitted for surgical pathology diagnosis. The cases were previously diagnosed as alveolar, embryonal, pleomorphic and undifferentiated subtypes. Formalinfixed paraffin-embedded sections were stained with antibody clone PTEN D4.3 (Cell Signaling Technology) at a 1:100 dilution after CC1 mild retrieval on a Benchmark Ultra instrument (Ventana, Tucson, AZ, USA).
Statistics
Data are presented as means ± s.d. Statistical comparisons were performed using unpaired two-tailed Student's t-tests, with a probability value of o0.05 taken to indicate significance.
